N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 4 ClinicalTrials.gov

Effect of Protocolized Magnesium Replacement on Mortality and Atrial Fibrillation in Critically Ill Patients

Sponsor: Scarborough General Hospital • ClinicalTrials.gov ID: NCT07173855

Registry updated: 2026-09-24
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

In patients with critical illness, such as severe infections, heart attacks, or respiratory failure, most intensive care units (ICUs) measure magnesium levels and give supplemental doses of magnesium when levels are below certain targets. However, the best targets are unknown. The goal of this clinical trial is to study protocols for magnesium supplementation in people with critical illness, comparing a protocol with higher target level to a protocol with a lower target level. The main question this study aims to answer is whether magnesium supplementation protocols targeting a higher or lower level lead to better 30-day survival and less atrial fibrillation. Participants will not have to do any specific tasks, undergo any additional tests, or complete any surveys.

Interventions

  • Magnesium sulfate administration (Drug)
    Magnesium sulfate is used in both arms for magnesium replacement.
  • Magnesium oxide (Drug)
    In the higher-target arm, magnesium oxide 420mg po q12h x 2 is one of the options available for magnesium replacement when magnesium levels lie between 0.75 and 0.95mmol/L.
  • Magnesium glucoheptonate (Drug)
    Magnesium glucoheptonate 30mL po q12h x 2 is an oral option for magnesium replacement in the higher-target arm.

Eligibility criteria

Inclusion Criteria: * Age 16 years or older * Admission orders written to a medical-surgical intensive care unit at a participating site * Magnesium replacement protocol ordered Exclusion Criteria: * Prior enrollment in or withdrawal from MAGNOLIA trial * Sustained ventricular tachycardia * Pre-eclampsia * Myasthenia gravis

Conditions

Critical Illness

Locations

  • Lakeridge Health Ajax-Pickering — Ajax, Ontario, Canada
  • Lakeridge Health Bowmanville — Bowmanville, Ontario, Canada
  • Lakeridge Health Oshawa — Oshawa, Ontario, Canada
  • Scarborough Centenary Hospital — Toronto, Ontario, Canada
  • Scarborough General Hospital — Toronto, Ontario, Canada
  • Scarborough Birchmount Hospital — Toronto, Ontario, Canada
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record